Abstract: Objective To study the clinical value of AR expression and its gene gain/lose in evaluating the prognosis of prostate cancer. Methods 19 patients were aged 58～90 years, and their PSA level before therapy were (13.3～120)ng/mL. As for gleason score, two had high differentiation (gleason score<7) and 17 had low differentiation (gleason score>=7).Using immunohistochemical and FISH method, we analyzed the expression of AR and its gene gain/lose in PC tissues from 19 samples. The correlation of AR expression and AR gene gain/lose with tumor prognosis in prostate cancer were analyzed in combination with the clinical data. Results 2 of 19 were found AR gene gain, the positive rate was 10.5%. The two positive samples were both from the survival group. However, none of the 6 samples from the death group was found AR gene gain. AR positive intensity of the unrecurent group were significantly higher than the death group(P<0.05). Conclusions Strong positive degree of AR expression in immunohistochemical test and AR gene gain occurring before therapy may be indicators for favorable prognosis in prostate cancer.

Key words: Prostate cancer, Prognosis, AR, Gene gain/lose